BR112018072579A2 - composto fenólico, composição farmacêutica, combinação do composto de fórmula i, e, usos de composto de fórmula i e de combinação - Google Patents

composto fenólico, composição farmacêutica, combinação do composto de fórmula i, e, usos de composto de fórmula i e de combinação

Info

Publication number
BR112018072579A2
BR112018072579A2 BR112018072579-0A BR112018072579A BR112018072579A2 BR 112018072579 A2 BR112018072579 A2 BR 112018072579A2 BR 112018072579 A BR112018072579 A BR 112018072579A BR 112018072579 A2 BR112018072579 A2 BR 112018072579A2
Authority
BR
Brazil
Prior art keywords
compound
formula
combination
derivatives
phenolic
Prior art date
Application number
BR112018072579-0A
Other languages
English (en)
Other versions
BR112018072579B1 (pt
Inventor
Ochoa Rodríguez Estael
Verdecia Reyes Yamila
Nuñez Figueredo Yanier
Ramírez Sánchez Jeney
Wong Guerra Maylin
Arturo Fonseca Fonseca Luis
Lázaro Pardo Andreu Gilberto
Amanda Canaán-Haden Navarro Claudia
Mondelo Rodríguez Abel
Gilberto Bárzaga Fernández Pedro
González Alfonso Nicté
Delgado Hernández René
Saúl Padrón Yaquis Alejandro
Original Assignee
Universidad De La Habana
Centro de Investigación Y Desarrollo de Medicamentos CIDEM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad De La Habana, Centro de Investigación Y Desarrollo de Medicamentos CIDEM filed Critical Universidad De La Habana
Publication of BR112018072579A2 publication Critical patent/BR112018072579A2/pt
Publication of BR112018072579B1 publication Critical patent/BR112018072579B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

a presente invenção refere-se à química, à farmácia, e, em particular, à produção de formulações a partir de derivados de compostos fenólicos ou de compostos polifenólicos e a partir de derivados de compostos fenólicos ou de compostos polifenólicos combinados com sistemas tricíclicos do tipo benzodiazepinas fundidas em derivados de 1,4-di-hidropiridinas com ação sobre os sistemas nervoso central e vascular. estas composições farmacêuticas apresentam ação gabaérgica, antiglutamatérgica, modulara dos canais de cálcio, mitoprotetora, antioxidante, anti-inflamatória e antiapoptótica, sendo utilizáveis no tratamento de distúrbios cardiovasculares, cerebrovasculares, neurodegenerativos, neuropsiquiátricos e neurológicos.
BR112018072579-0A 2016-05-04 2017-05-03 Composto fenólico, composição farmacêutica, combinação do composto de fórmula i, e, usos de composto de fórmula i e de combinação BR112018072579B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU2016-0059 2016-05-04
CU2016000059A CU24576B1 (es) 2016-05-04 2016-05-04 Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular
PCT/CU2017/050003 WO2017190714A1 (es) 2016-05-04 2017-05-03 Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular

Publications (2)

Publication Number Publication Date
BR112018072579A2 true BR112018072579A2 (pt) 2019-02-19
BR112018072579B1 BR112018072579B1 (pt) 2024-02-20

Family

ID=60202803

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072579-0A BR112018072579B1 (pt) 2016-05-04 2017-05-03 Composto fenólico, composição farmacêutica, combinação do composto de fórmula i, e, usos de composto de fórmula i e de combinação

Country Status (19)

Country Link
US (1) US10722491B2 (pt)
EP (1) EP3453704B1 (pt)
JP (1) JP6997995B2 (pt)
KR (1) KR102416478B1 (pt)
CN (1) CN109476627B (pt)
AR (1) AR108370A1 (pt)
AU (1) AU2017259749C1 (pt)
BR (1) BR112018072579B1 (pt)
CA (1) CA3023073C (pt)
CL (1) CL2018003114A1 (pt)
CO (1) CO2018011927A2 (pt)
CU (1) CU24576B1 (pt)
EA (1) EA037951B1 (pt)
ES (1) ES2878579T3 (pt)
MX (1) MX2018013422A (pt)
PH (1) PH12018502327A1 (pt)
SG (1) SG11201809843SA (pt)
WO (1) WO2017190714A1 (pt)
ZA (1) ZA201808161B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20160058A7 (es) 2016-05-04 2017-12-08 Centro De Investigación Y Desarrollo De Medicamentos (Cidem) Organizacion Superior De Desarrollo Emp Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular
MX2022008001A (es) * 2019-12-26 2022-07-21 Centro De Investig Y Desarrollo De Medicamentos Cidem Uso de un derivado benzodiacepinico y metodo de tratamiento de la lesion traumatica cerebral.
CU20190114A7 (es) 2019-12-26 2021-08-06 Centro De Investig Y Desarrollo De Medicamentos Cidem Combinación para simultáneamente incrementar la eficacia analgésica de la morfina y reducir su dependencia física

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281714A (en) 1990-08-16 1994-01-25 American Home Products Corporation N,N',N'-trisubstituted-5-bisaminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-CoA: cholesterol-acyl transferase
MX9204939A (es) 1991-09-06 1993-03-01 American Home Prod Inhibidores 5-bis-aminometilen-1,3-dioxan-4,6-diona n,n',n'-trisubstituidas, de la acil coenzima a: colesterol-aciltransferasa.
ES2074770T3 (es) 1992-07-17 1995-09-16 Biogal Gyogyszergyar Procedimiento de preparacion de derivados de 1,3-dioxano-4,6-diona.
JPH11180975A (ja) 1997-10-13 1999-07-06 Chemiprokasei Kaisha Ltd アミノメチレンジオキサン誘導体、その製造方法および用途
EA011010B1 (ru) 2004-02-27 2008-12-30 Эмджен, Инк. Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина
JP2007063444A (ja) * 2005-08-31 2007-03-15 Tdk Corp 錯化合物及びこれを用いた光記録媒体

Also Published As

Publication number Publication date
AR108370A1 (es) 2018-08-15
KR20210025138A (ko) 2021-03-09
PH12018502327A1 (en) 2019-09-02
CL2018003114A1 (es) 2019-06-14
US10722491B2 (en) 2020-07-28
CU20160059A7 (es) 2017-12-08
AU2017259749B2 (en) 2021-08-19
ZA201808161B (en) 2021-10-27
ES2878579T3 (es) 2021-11-19
EP3453704B1 (en) 2021-06-16
EA037951B1 (ru) 2021-06-11
AU2017259749C1 (en) 2021-12-02
MX2018013422A (es) 2019-08-16
CA3023073C (en) 2022-08-30
EA201892462A1 (ru) 2019-07-31
CN109476627A (zh) 2019-03-15
JP2019516791A (ja) 2019-06-20
US20190133996A1 (en) 2019-05-09
CU24576B1 (es) 2022-02-04
AU2017259749A1 (en) 2018-12-20
SG11201809843SA (en) 2018-12-28
KR102416478B1 (ko) 2022-07-04
BR112018072579B1 (pt) 2024-02-20
WO2017190714A1 (es) 2017-11-09
JP6997995B2 (ja) 2022-02-04
CN109476627B (zh) 2021-06-15
CA3023073A1 (en) 2017-11-09
CO2018011927A2 (es) 2019-02-08
EP3453704A1 (en) 2019-03-13

Similar Documents

Publication Publication Date Title
BR112018074185A2 (pt) 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas
CY1124828T1 (el) Αλλοστερικοι διαμορφωτες των νικοτινικων υποδοχεων ακετυλχολινης
BR112018076534A2 (pt) compostos heterocíclicos como imunomoduladores
BR112018072579A2 (pt) composto fenólico, composição farmacêutica, combinação do composto de fórmula i, e, usos de composto de fórmula i e de combinação
BR112016026809A2 (pt) compostos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol substituído como agentes de alvejamento de asgpr
MX2020013853A (es) Compuestos innovadores.
GT200900294A (es) Compuestos amino-heterocíclicos
MA45153B1 (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
EA201592024A1 (ru) Замещенные 5-(3,5-диметилизоксазол-4-ил)-индолин-2-оны
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
CL2009000975A1 (es) Compuestos derivados de quinuclidina, ligandos del receptor de acetilcolina a7; su composicion farmaceutica; su uso para el tratamiento de trastornos del sistema nervioso central, en especial afectivos y neurodegenerativos, enfermedades tales como esquizofrenia y alzheimer.
CL2019001658A1 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
CL2019001891A1 (es) Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas.
BR112015021429A2 (pt) compostos antivirais
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
CL2018000783A1 (es) Nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen
BR112018009550A2 (pt) derivados de 1,4-benzodiazepinona tricíclica substituída como moduladores alostéricos de receptores de glutamato metabotrópico de grupo ii
BR112020022088A8 (pt) Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina
WO2018083635A3 (en) Tricyclic heterocyclic derivatives and uses thereof
BR112018073219A2 (pt) Composto de fórmula i, composição farmacêutica, processo para síntese destescompostos e uso dos mesmos
PH12019502850A1 (en) AMIDE DERIVATIVES AS Nav1.7 AND Nav1.8 BLOCKERS
BR112015028516A2 (pt) tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
UY36347A (es) Compuestos y su uso como inhibidores de bace
GT200600425A (es) Compuestos de imidazol para el tratamiento de trastornos neurologicos

Legal Events

Date Code Title Description
B15V Prolongation of time limit allowed

Free format text: TENDO EM VISTA A PORTARIA INPI PR NO 120 DE 16/03/2020, PORTARIA INPI PR NO 161 DE 13/04/2020; PORTARIA INPI PR NO 166 DE 27/04/2020 E PORTARIA INPI PR NO 179 DE 11/05/2020, QUANTO A SUSPENSAO DOS PRAZOS VENCIDOS ENTRE 16/03/2020 A 31/05/2020, DEVOLVE-SE O PRAZO NESSE PEDIDO COM RELACAO A SOLICITACAO DO PEDIDO DE EXAME.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/05/2017, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2772 DE 20/02/2024 QUANTO AO TITULO.